Skip to main content
ARTIVION, INC. logo

ARTIVION, INC. — Investor Relations & Filings

Ticker · AORT ISIN · US2289031005 LEI · 549300YTKV8DMSMG6K81 US Manufacturing
Filings indexed 1,531 across all filing types
Latest filing 2024-01-31 Director's Dealing
Country US United States of America
Listing US AORT

About ARTIVION, INC.

https://artivion.com/

Artivion, Inc. is a medical device company focused on developing, manufacturing, and distributing solutions for cardiac and vascular surgery. The company has an intentional focus on creating technologies to treat diseases of the aorta. In collaboration with surgeons, Artivion develops products designed to address complex surgical challenges. Its portfolio includes a range of aortic-centric technologies, such as heart valve solutions, implantable human tissues (allografts), surgical sealants, and various stent grafts for the aortic arch, thoracoabdominal, abdominal, and peripheral aorta. The company's purpose is to provide simple, elegant solutions that improve surgical outcomes for patients with aortic diseases.

Recent filings

Filing Released Lang Actions
FORM 5
Director's Dealing
2024-01-31 English
FORM 5
Director's Dealing
2024-01-31 English
FORM 5
Director's Dealing
2024-01-31 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-01-22 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 18, 2024, reporting the entry into a material definitive agreement, specifically a Credit and Guaranty Agreement involving new credit facilities and loan borrowings. The content focuses on financing activities, including loan amounts, terms, interest rates, covenants, and related financial obligations. There is no detailed financial performance data or comprehensive financial statements, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a report of management or board changes, legal proceedings, or voting results. The primary subject is the update on the company's financing arrangements and capital structure changes. Therefore, the document fits best under the category Capital/Financing Update (CAP). The document length (8897 characters) supports it being a substantive filing rather than a brief announcement. Confidence is high given the clear focus on financing terms and credit facilities.
2024-01-18 English
FORM 4
Director's Dealing
2024-01-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.